Compare BRN & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BRN | LSTA |
|---|---|---|
| Founded | 1956 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Misc Health and Biotechnology Services |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.7M | 15.9M |
| IPO Year | 1995 | 2000 |
| Metric | BRN | LSTA |
|---|---|---|
| Price | $0.87 | $1.00 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 98.4K | 78.9K |
| Earning Date | 08-11-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 20.42 |
| EPS | ★ N/A | N/A |
| Revenue | $13,697,000.00 | ★ $35,283,868.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 56.90 |
| 52 Week Low | $0.84 | $0.96 |
| 52 Week High | $1.40 | $5.07 |
| Indicator | BRN | LSTA |
|---|---|---|
| Relative Strength Index (RSI) | 40.09 | 34.39 |
| Support Level | $0.84 | $0.99 |
| Resistance Level | $1.11 | $1.28 |
| Average True Range (ATR) | 0.06 | 0.10 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 22.31 | 11.02 |
Barnwell Industries Inc is an oil and gas company engaged in the acquisition, development, production, and sale of crude oil and natural gas. The Company operates through two segments: the Oil and Natural Gas segment, which focuses on oil and natural gas development, production, acquisitions, and sales in the United States and Canada; and the Land Investment segment, which owns leasehold land interests in Hawaii. The Company generates the majority of its revenue from the Oil and Natural Gas segment. The company operates in two geographic regions, the United States and Canada, with Canada contributing the majority of revenue.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The company has one operating segment, the research and development of its investigational drug product.